[Bis-(hydroxy-2-ethylthyo)-1,10-decano in hyperlipaemic therapy (author's transl)].
The authors studied the effectiveness and biological tolerability of Tiadenol [Bis-(hydroxy-2-ethylthyo)-1,10-decano] against clofibrate, in a group of 38 hyperlipaemic (volunteers) subjects, with or without atherosclerotic disease. The results showed that the new hypolipidaemic drug has a great effect on cholesterolemia and trigliceridaemia, as does clofibrate. The statistic examination confirmed the results. This research didn't show any side-effects of the drug, which has a very good biological tolerability.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use; D003651:Decanoates / Q000494:pharmacology; D004341:Drug Evaluation; D004361:Drug Tolerance; D005233:Fatty Alcohols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D014280:Triglycerides / Q000097:blood
D003651:Decanoates; D005233:Fatty Alcohols; D000960:Hypolipidemic Agents; D014280:Triglycerides; C004568:tiadenol; D002784:Cholesterol; D002994:Clofibrate
Il bis-(idrossi-2-etiltio)-1,10-decano nella terapia delle iperlipemie